FDA clears GE's contrast-enhanced mammo technology
GE Healthcare’s SenoBright Contrast Enhanced Spectral Mammography (CESM) has received FDA 510(k) clearance.
SenoBright CESM technology is designed to produce contrast-enhanced images of the breast using a legally approved x-ray contrast agent and a dual energy acquisition technique. It uses x-rays at multiple energies to create two separate but almost simultaneous exposures. One image looks like a standard mammography image and a second image shows the contrast enhanced areas that can help localize a lesion.
SenoBright was originally launched in 2010 and is in use at 17 mammography centers throughout Europe and Japan, according to Waukesha, Wis.-based GE Healthcare.
GE estimated that by 2020, more than one million women worldwide will be examined using SenoBright.
SenoBright CESM technology is designed to produce contrast-enhanced images of the breast using a legally approved x-ray contrast agent and a dual energy acquisition technique. It uses x-rays at multiple energies to create two separate but almost simultaneous exposures. One image looks like a standard mammography image and a second image shows the contrast enhanced areas that can help localize a lesion.
SenoBright was originally launched in 2010 and is in use at 17 mammography centers throughout Europe and Japan, according to Waukesha, Wis.-based GE Healthcare.
GE estimated that by 2020, more than one million women worldwide will be examined using SenoBright.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.